<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Iran Med</journal-id><journal-id journal-id-type="iso-abbrev">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">AIM</journal-id><journal-title-group><journal-title>Archives of Iranian Medicine</journal-title></journal-title-group><issn pub-type="ppub">1029-2977</issn><issn pub-type="epub">1735-3947</issn><issn-l>1029-2977</issn-l><publisher><publisher-name>Academy of Medical Sciences of I.R. Iran</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40001327</article-id><article-id pub-id-type="pmc">PMC11862391</article-id><article-id pub-id-type="doi">10.34172/aim.33366</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Gastroenteropancreatic Neuroendocrine Tumors: Does Tumor Location Affect Prognosis?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2935-8463</contrib-id><name><surname>Ozsoy</surname><given-names>Mehmet Sait</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/software/">Software</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0955-9615</contrib-id><name><surname>Erol</surname><given-names>Cem Ilgin</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0240-0924</contrib-id><name><surname>Aydemir</surname><given-names>Muhammet Ali</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3604-6177</contrib-id><name><surname>Baysal</surname><given-names>Hakan</given-names></name><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7567-3117</contrib-id><name><surname>Buyuker</surname><given-names>Fatih</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1429-6776</contrib-id><name><surname>Seneldir</surname><given-names>Hatice</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="A03" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2020-1913</contrib-id><name><surname>Ekinci</surname><given-names>Ozgur</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7651-4321</contrib-id><name><surname>Eren</surname><given-names>Tunc</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2130-2529</contrib-id><name><surname>Alimoglu</surname><given-names>Orhan</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="A01">
<sup>1</sup>Department of General Surgery, Faculty of Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey</aff><aff id="A02">
<sup>2</sup>Department of General Surgery, Erzurum City Hospital, Erzurum, Turkey</aff><aff id="A03">
<sup>3</sup>Department of Pathology, Faculty of Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey</aff><author-notes><corresp id="COR1">
<label>*</label><bold>Corresponding Author:</bold> Muhammet Ali Aydemir, Email: <email>maliaydemir1990@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>1</month><year>2025</year></pub-date><volume>28</volume><issue>1</issue><fpage>29</fpage><lpage>39</lpage><history><date date-type="received"><day>27</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Author(s).</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="https://journalaim.com">https://journalaim.com</self-uri><abstract><sec id="sa1"><title>Background:</title><p> Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare entities. Generally, they can be localized anywhere in the gastrointestinal or hepatobiliary tract. The purpose of our study is to evaluate the effect of tumor location on prognosis in patients with GEP-NET undergoing surgery. Our secondary objective is to examine other factors affecting the prognosis of patients with GEP-NET.</p></sec><sec id="sa2"><title>Methods:</title><p> We retrospectively analyzed data from 30 patients with GEP-NET who underwent surgery in the General Surgery Clinic between 2012 and 2022. The gNET group (n=18) included tumors located in the gastrointestinal tract, while the pNET group (n=12) included tumors located in the hepatopancreatobiliary system. Surgical, laboratory, radiological, and pathological findings of the patients, as well as follow-up outcomes were recorded and statistically analyzed.</p></sec><sec id="sa3"><title>Results:</title><p> In subgroup comparison, tumor size was found to be larger in the pNET group (<italic toggle="yes">P</italic>=0.002). The statistical analysis of recurrence (16.7% versus 33.3%) and mortality rates (16.7% versus 41.7%) between the subgroups (<italic toggle="yes">P</italic>=0.329 and <italic toggle="yes">P</italic>=0.210, respectively) did not reveal a significant difference. When all patients were evaluated, it was observed that advanced age, presence of carcinoma diagnosis, higher tumor grade, advanced TNM stage, larger tumor size, presence of lymphovascular or perineural invasion, elevated mitotic index, higher Ki-67 index, and having received adjuvant therapy increased the rates of recurrence and mortality. </p></sec><sec id="sa4"><title>Conclusion:</title><p> There was no statistically significant difference in survival outcomes between the GEP-NET groups located in the gastrointestinal tract and the hepatopancreatobiliary system.</p></sec></abstract><kwd-group><kwd>Digestive system</kwd><kwd>General surgery</kwd><kwd>Neuroendocrine tumors</kwd></kwd-group></article-meta><notes><p>
<bold>Cite this article as:</bold> Ozsoy MS, Erol CI, Aydemir MA, Baysal H, Buyuker F, Seneldir H, et al. Gastroenteropancreatic neuroendocrine tumors: does tumor location affect prognosis?. Arch Iran Med. 2025;28(1):29-39. doi: 10.34172/aim.33366</p></notes></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p> Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare group of diseases.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Reported on a series of 64&#x02005;971 intrabdominal neuroendocrine tumors (iNETs), the annual age-adjusted incidence increased from 1.09 per 100&#x02005;000 to 6.98 per 100&#x02005;000 between 1973 and 2012.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> The most common locations of GEP-NETs are the small intestine (30.8%), rectum (26.3%), colon (17.6%), pancreas (12.1%), and appendix (5.7%).<sup><xref rid="R3" ref-type="bibr">3</xref></sup></p><p> In general, GEP-NETs can be localized anywhere in the gastrointestinal tract or hepatopancreatobiliary system, and the symptoms they cause are closely related to the location where the tumor develops. Since these tumors progress relatively slowly, they are more likely to be detected incidentally without causing symptoms.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Gastrointestinal tract neuroendocrine tumors (gNETs) are often detected through non-specific findings in screening endoscopies and sometimes incidentally during the examination of appendectomy specimens.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Nearly 40% of NETs located in the hepatopancreatobiliary system (pNETs) are detected incidentally.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> While pNETs are generally hormonally silent, they can produce various peptide hormones, including glucagon, insulin, and gastrin, potentially leading to clinical syndromes related to these hormones.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p><p> Gastrointestinal tract NETs take their origin from enterochromaffin cells, whereas pNETs are believed to arise from the islets of Langerhans. However, another hypothesis suggests that pNETs may originate from precursor cells in the ductal epithelium.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Small intestine NETs have a relatively higher malignancy potential but tend to progress slowly in a metastatic setting. In contrast, gastric and rectal NETs generally exhibit a lower propensity for metastasis; however, they can progress rapidly once metastasis occurs.<sup><xref rid="R4" ref-type="bibr">4</xref></sup></p><p> The SEER database reports that at diagnosis, 53% of GEP-NET patients present with localized disease, 20% with local disease, and 27% with distant metastasis.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Tumor grade is defined as follows: low-grade (G1) tumors have a mitotic index of 0&#x02012;1/2 mm<sup>2</sup> or a Ki-67 proliferation index of 0&#x02012;2%; intermediate (G2) tumors have a mitotic index of 2&#x02012;20/2 mm<sup>2</sup> or a Ki-67 proliferation of 3&#x02012;20%; and high-grade (G3) tumors show a mitotic index greater than 20/2 mm<sup>2</sup> or a Ki-67 proliferation index exceeding 20%.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> The World Health Organization (WHO) classifies NETs as G1 and G2 which are considered well-differentiated, while G3 tumors are classified as poorly differentiated.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Generally, early-stage GEP-NETs have a good prognosis, while tumor grade and location significantly influence the survival of patients with metastatic disease.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Rectal NETs were reported have a better prognosis when compared to lesions in other locations, whereas pancreatic NETs had the worst prognosis.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p><p> In local or locoregional GEP-NETs, the preferred treatment is surgical resection with safe margins. For symptomatic pNETs larger than 2 cm, or for intermediate-high grade pNETs, a Whipple procedure or distal pancreatectomy should be performed depending on the location. Enucleation is another surgical option for these patients, but it poses higher risks regarding achieving safe surgical margins and lymph node dissection.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Conversely, the treatment approach for low-grade, non-functioning, pNETs smaller than 2 cm is still debated. Some guidelines advocate for radical surgical resection of these tumors, while the European Neuroendocrine Tumor Society (ENETS) guidelines recommend surveillance for this patient group.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> In the management of gNETs, the most crucial determining factor is the tumor&#x02019;s location. For jejunal and proximal ileal gNETs, segmental small bowel resections are performed. For tumors near or infiltrating the ileocecal valve, a right hemicolectomy is indicated.</p><p> In about 25% of cases, multifocality is reported; therefore, during resections for gNETs, other bowel segments should be carefully inspected and palpated as means of formal surgical exploration. During these resections, including the mesentery is necessary for proper lymph node evaluation.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> As a general rule, for appendiceal NETs smaller than 1 cm, an appendectomy is considered sufficient. For tumors larger than 2 cm, a right hemicolectomy is recommended. For tumors of intermediate size (1&#x02012;2 cm) with significant mesoappendix invasion or those located at the base of the appendix, a right hemicolectomy should also be considered.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> For colonic gNETs, a formal colectomy should be performed.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> For rectal gNETs smaller than 2 cm, endoscopic or transanal resections can be planned. However, for larger tumors, abdominoperineal resection or low anterior resection should be performed with lymph node dissection.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p><p> In advanced tumors, medical therapy plays a crucial role in symptom control and prolonging survival in patients with locally advanced or metastatic GEP-NETs. Some somatostatin analogs, including octreotide and lanreotide, are commonly used as first-line treatments to alleviate symptoms related to hormone hypersecretion and to inhibit tumor growth by binding to somatostatin receptors on tumor cells.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p><p> The first aim of the present study is to evaluate the impact of tumor location on the prognosis of patients with GEP-NETs who underwent surgery. The secondary objective of the study is to investigate other factors influencing the prognosis of patients with GEP-NETs.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><p> As shown in <xref rid="F1" ref-type="fig">Figure 1</xref>, we retrospectively evaluated the historical records of 30 patients, who underwent surgery in the Department of General Surgery between 2012&#x02012;2022 and were reported as GEP-NET based on postoperative histopathological examinations. Data including intraoperative findings, early postoperative follow-ups, laboratory results, radiological imaging, and pathology reports were recorded. All patients were reached by phone and invited to regular follow-up visits at intervals of 6 months to the surgical oncological outpatient clinic as their clinical, laboratory and radiological and findings were documented simultaneously. Additionally, long-term follow-up results, including disease-free survival (DFS) and overall survival (OS) were recorded and evaluated.</p><fig position="float" id="F1"><label>Figure 1</label><graphic xlink:href="aim-28-29-g001" position="float"/><statement><p>
Patient Selection Flowsheet</p></statement></fig><p> Patients were divided into two subgroups based on the tumor locations reported in the postoperative pathological examinations as the gNET group (tumors located along the gastrointestinal tract) and the pNET group (tumors located in the hepatopancreatobiliary system). Patients lost to follow-up, patients under 18 years of age, and those with incomplete data were excluded.</p><p> All statistical analyses were conducted using the R version 3.6.1 (A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; <uri xlink:href="https://www.R-project.org">https://www.R-project.org</uri>). Normality was assessed using the Shapiro-Wilk test and histograms. Depending on the normal distribution, either Student&#x02019;s <italic toggle="yes">t</italic>-test or the Mann-Whitney U test was applied to compare continuous variables. Categorical variables were analyzed using Fisher&#x02019;s exact test or Pearson&#x02019;s chi-square test. Kaplan-Meier curves were generated for OS and DFS based on tumor location. A <italic toggle="yes">P</italic>-value of&#x02005;&#x0003c;&#x02005;0.05 was considered statistically significant. Post hoc power analysis was conducted for the effect of location for recurrence and mortality using OpenEpi version 3.01 (<uri xlink:href="https://www.openepi.com/">https://www.openepi.com/</uri>).</p></sec><sec sec-type="results" id="s3"><title>Results</title><p> The study group consisted of 16 (53.3%) men and 14 (46.7%) women with a mean age of 51.7&#x02005;&#x000b1;&#x02005;18.9 (median: 48, range: 19&#x02012;79) years. Among these patients, 53.3% (n&#x02005;=&#x02005;16) had comorbidities, with hypertension being the most common (n&#x02005;=&#x02005;7, 23.3%). A history of previous abdominal surgery was present in 10 (33.3%) patients. Postoperative histopathological examinations revealed that 24 (80%) of the patients had NET and 6 (20%) had NEC. Lymph node metastasis was observed in 10 (33.3%) patients, while distant metastasis was found in 3 (10%) patients. The appendix was the most common tumor location in 12 (40%) patients, followed by the pancreas in 9 (30%) patients, and the stomach in 2 (6.6%) patients (<xref rid="T1" ref-type="table">Table 1</xref>). After categorizing the patients into the gNET and pNET subgroups, it was found that 18 (60%) patients belonged to the gNET group and 12 (40%) to the pNET group. Three (10%) patients underwent reoperation post-surgery. The number of patients receiving adjuvant therapy was 8 (26.7%), and recurrence was observed in 7 (23.3%) patients. The mean OS was calculated as 54.7&#x02005;&#x000b1;&#x02005;37.9 months, and the mean DFS was 52.5&#x02005;&#x000b1;&#x02005;40.1 months. For cases identified as metastatic, the mean OS was 29.3&#x02005;&#x000b1;&#x02005;25.7 (range: 13&#x02012;59) months.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Demographics and Descriptive Parameters
</title></caption><table frame="hsides" rules="none"><tbody><tr><th colspan="3" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Parameter</bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>N </bold>(%)</th></tr><tr><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Mean&#x000b1;SD</bold>
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Age (y)</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">51.7&#x02005;&#x000b1;&#x02005;18.9</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>n (%)</bold>
</italic>
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Gender</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Men</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (53.3) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Women</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (46.7) </td></tr><tr><td rowspan="7" style="text-align:left;vertical-align:middle;" colspan="1">Comorbidity</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Diabetes mellitus</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (13.3)</td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1">16 (53.3)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hypertension</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (23.3)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Coronary artery disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (6.7)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic kidney disease </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hyperlipidemia</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="6" style="text-align:left;vertical-align:middle;" colspan="1">Surgical history</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Appendectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3)</td><td rowspan="6" style="text-align:center;vertical-align:middle;" colspan="1">10 (33.3)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cholecystectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Colectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Herniorrhaphy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (6.7)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cesarean section</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (13.3)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Pathologic diagnosis</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine tumor</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">24 (80.0) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine carcinoma</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (20.0) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">Tumor grade</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (48.1) </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">27 (90.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (37.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (14.8)</td></tr><tr><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">AJCC stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (50.0) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (16.7)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (23.3)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">T stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (53.3) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (30.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (6.7)</td></tr><tr><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">N stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">20 (66.7) </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (23.3)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">M stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (90.0) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0)</td></tr><tr><td rowspan="10" style="text-align:left;vertical-align:middle;" colspan="1">Tumor location</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Ampulla vateri</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3) </td><td rowspan="10" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Appendix</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (40.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Caecum </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Pancreas</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (30.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Jejunum</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Liver</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Colon</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Stomach</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (6.7)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Rectum</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Gallbladder</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (3.3) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Tumor group</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">gNET</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18 (60.0) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">pNET</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (40.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Multicentricity</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Lymphovascular invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (40.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Perineural invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (36.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Synaptophysin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Chromogranin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (96.4) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Neural cell adhesion molecule 1 (CD56) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (83.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (40.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Reoperation history</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (10.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Adjuvant therapy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (26.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Recurrence</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (23.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Tumor size (cm)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.4&#x02005;&#x000b1;&#x02005;2.5</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Mitosis rate (#)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5.73&#x02005;&#x000b1;&#x02005;9.9</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Ki-67 (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15.7&#x02005;&#x000b1;&#x02005;28.0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Overall survival (months)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54.7&#x02005;&#x000b1;&#x02005;37.9</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1">Disease-free survival (months)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">52.5&#x02005;&#x000b1;&#x02005;40.1</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">30 (100.0)</td></tr></tbody></table><table-wrap-foot><fn><p> N, Number of patients analyzed; n, Number of patients; SD, Standard deviation; gNET, Gastrointestinal neuroendocrine tumor; pNET, Hepatopancreatobiliary neuroendocrine tumor</p></fn></table-wrap-foot></table-wrap><p> Statistical comparisons of the data from the two subgroups are presented in <xref rid="T2" ref-type="table">Table 2</xref>. No statistically significant differences were found between the gNET and pNET groups in terms of age, gender, comorbidities, previous surgeries, pathological diagnosis, tumor grade, TNM stages, multicentricity, or mitotic index. However, tumor diameter was significantly larger in the pNET group (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.002). Additionally, no significant differences were observed in recurrence and mortality rates between the two subgroups (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.329 and <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.210, respectively). Although the gNET group had more than double the median OS [61.1 (range: 9.7-110.0) months] and DFS [61.1 (range: 5.4&#x02012;110.0) months] compared to the pNET group (OS: 30.5 [1.7; 121.0] months, DFS: 25.8 [1.7; 121.0] months), this difference did not achieve statistical significance (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.421 and <italic toggle="yes">P</italic>=&#x02005;0.446, respectively).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><title>Comparison of the subgroups according to their demographic, pathologic, surgical and prognostic parameters
</title></caption><table frame="hsides" rules="none"><tbody><tr><th colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Parameter</bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>gNET (n=18) </bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>pNET (n=12) </bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>N (%)</bold>
</th></tr><tr><th colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Median [min; max] </bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Median [min; max]</bold>
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1">Age (years)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">43.0 [19.0;77.0]</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">63.5 [36.0;79.0]</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1"> 0.094 </td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
<bold> n (%) </bold>
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
<bold>n (%) </bold>
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Gender</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Women</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (44.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (50.0) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">1.000 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Men</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (55.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (50.0) </td></tr><tr><td rowspan="7" style="text-align:left;vertical-align:middle;" colspan="1">Comorbidity</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Diabetes mellitus</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hypertension</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (33.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.392 </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Coronary artery disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (5.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (8.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (5.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic kidney disease </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (8.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.400 </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hyperlipidemia</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (5.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.548 </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (8.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td></tr><tr style="background-color:#e3e8e1"><td rowspan="6" style="text-align:left;vertical-align:middle;" colspan="1">Surgical history</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Appendectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (8.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.400 </td><td rowspan="6" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cholecystectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (5.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.548 </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Colectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (8.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.400 </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Herniorrhaphy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.503 </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cesarean section</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (5.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Pathologic diagnosis</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine tumor</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (83.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (75.0) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.660 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine carcinoma</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (16.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (25.0) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">Tumor grade</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (52.9) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (40.0) </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">0.762 </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">27 (90.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (35.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (40.0) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (20.0)</td></tr><tr><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">AJCC stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (55.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (41.7) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">0.853 </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (16.7) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (33.3) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (8.3)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">T stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (61.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (41.7) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">0.090 </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (25.0) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (27.8) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (33.3) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.00) </td></tr><tr><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">N stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (72.2) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (58.3) </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">0.120 </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (41.7) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">M stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (88.9) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (91.7) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">1.000 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (11.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (8.3)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Multicentricity</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (16.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.255 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Lymphovascular invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (33.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (50.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.458 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Perineural invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (33.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (41.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.712 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Synaptophysin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> - </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Chromogranin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (91.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.429 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Neural cell adhesion molecule 1 (CD56) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (83.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (83.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (40.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Reoperation history</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 3 (16.7%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0 (0.00%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.255 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Adjuvant therapy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 5 (27.8%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 3 (25.0%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.000 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Recurrence</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 3 (16.7%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 4 (33.3%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.392 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Mortality rate</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 3 (16.7%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 5 (41.7%) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.210 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
<bold>Median [min; max] </bold>
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
<bold>Median [min; max]</bold>
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Tumor size <italic toggle="yes">(cm)</italic></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.8 [0.3; 6.5] </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.8 [1.0; 11.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.002 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Mitosis rate (#)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.0 [0.0; 30.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.0 [0.0; 33.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.294 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Ki-67 (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.0 [0.0; 90.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5.0 [1.0; 85.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.150 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Overall survival (months)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">61.1 [9.7; 110.0] </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30.5 [1.7; 121.0] </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.421 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1">Disease-free survival (months)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">61.1 [5.4; 110.0] </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">25.8 [1.7; 1210.] </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.446 </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">30 (100.0)</td></tr></tbody></table><table-wrap-foot><fn><p> N, Number of patients analyzed; n, Number of patients; Median [min; max], Median [minimum; maximum]; gNET, Gastrointestinal neuroendocrine tumor; pNET, Hepatopancreatobiliary neuroendocrine tumor.</p></fn></table-wrap-foot></table-wrap><p> The statistical analyses to determine factors influencing prognosis, including recurrence and mortality, are provided in <xref rid="T3" ref-type="table">Tables 3</xref> and <xref rid="T4" ref-type="table">4</xref>. It was observed that advanced age, carcinoma diagnosis, higher tumor grade, advanced stages, larger tumor diameter, presence of lymphovascular or perineural invasion, increased mitotic index, higher Ki-67 values, and receiving adjuvant therapy were factors that increased both recurrence and mortality rates (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.050). Tumor group was not found to be a significant factor for recurrence and mortality (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.392 and <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.210, respectively). Notably, the presence of hypertension significantly increased mortality (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.007). Additionally, the development of recurrence also increased mortality rates (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><title>Comparison of the Parameters Affecting Recurrence
</title></caption><table frame="hsides" rules="none"><tbody><tr><th rowspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<bold>Parameters</bold>
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Recurrence</bold>
</th><th rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
</th><th rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<bold>N </bold>(%)</th></tr><tr><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>No (n=23)</bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Yes (n=7)</bold>
</th></tr><tr><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Median [min; max] </bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Median [min; max]</bold>
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Age <italic toggle="yes">(years)</italic></td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">42.0 [19.0; 79.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">75.0 [61.0; 78.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.001 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>n (%)</bold>
</italic>
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>n (%)</bold>
</italic>
</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Gender</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Women</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (43.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (57.1) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.675 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Men</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (56.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (42.9) </td></tr><tr><td rowspan="7" style="text-align:left;vertical-align:middle;" colspan="1">Comorbidity</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Diabetes mellitus</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (8.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1">0.007 </td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hypertension</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (85.7) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Coronary artery disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (8.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.3) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic kidney disease </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hyperlipidemia</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.5) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (8.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.3) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="6" style="text-align:left;vertical-align:middle;" colspan="1">Surgical history</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Appendectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.3) </td><td rowspan="6" style="text-align:center;vertical-align:middle;" colspan="1">0.002 </td><td rowspan="6" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cholecystectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Colectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.3) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Herniorrhaphy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.3) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cesarean section</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.3) </td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Pathologic diagnosis</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine tumor</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (95.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1"> 0.001 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine carcinoma</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (71.4)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">Tumor grade</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (56.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">&#x02005;&#x0003c;&#x02005;0.001 </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">27 (90.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (39.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.3) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (57.1)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td></tr><tr><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">AJCC stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (60.9) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.2) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1"> 0.002 </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (21.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (17.4) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (42.9) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (42.9) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">T stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (65.2) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.2) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1"> 0.006 </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (30.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td></tr><tr><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">N stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">19 (82.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (14.2) </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1"> 0.002 </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (57.2) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (28.6) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">M stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (57.1) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1"> 0.009 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (42.9) </td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Tumor group</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">gNET</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (65.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (42.9)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1"> 0.392 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">pNET</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (34.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (57.1) </td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Multicentricity</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 1.000 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Lymphovascular invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (26.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (85.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.009 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Perineural invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (21.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (85.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.004 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Synaptophysin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">21 (91.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Chromogranin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">21 (91.3) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (85.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.250 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Neural cell adhesion molecule 1 (CD56) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (26.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (57.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.515 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (40.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Reoperation history</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 1.000 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Adjuvant therapy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (8.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (85.7) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Tumor size (cm)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.9 [0.30; 7.00]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.0 [1.00; 11.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.020 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Mitosis rate (#)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.0 [0.00; 33.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16.0 [1.00; 32.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.003 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1">Ki-67 (%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">2.0 [0.00; 80.0]</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">25.0 [3.00; 90.0]</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1"> 0.001 </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">30 (100.0)</td></tr></tbody></table><table-wrap-foot><fn><p> N, Number of patients analyzed; n, Number of patients; Median [min; max], Median [minimum; maximum]; gNET, Gastrointestinal neuroendocrine tumor; pNET, Hepatopancreatobiliary neuroendocrine tumor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><title>Comparison of the Parameters Affecting Mortality
</title></caption><table frame="hsides" rules="none"><tbody><tr><th rowspan="2" colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;">
<bold>Parameters</bold>
</th><th colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Mortality</bold>
</th><th rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<italic toggle="yes">
<bold>P </bold>
</italic>
</th><th rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<bold>N </bold>(%)</th></tr><tr><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>No (n=22)</bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Yes (n=8)</bold>
</th></tr><tr><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Median [min; max] </bold>
</th><th style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Median [min; max]</bold>
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th><th style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</th></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Age (years)</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">40.0 [19.0; 79.0]</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">72.5 [66.0; 78.0]</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001 </td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Gender</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Women</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (40.9) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (62.5) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1"> 0.417 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Men</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (59.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (37.5) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="7" style="text-align:left;vertical-align:middle;" colspan="1">Comorbidity</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Diabetes mellitus</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (9.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (25.0) </td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1"> 0.003 </td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hypertension</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (9.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (62.5) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Coronary artery disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Chronic kidney disease </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Hyperlipidemia</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (9.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (9.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr><td rowspan="6" style="text-align:left;vertical-align:middle;" colspan="1">Surgical history</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Appendectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td rowspan="6" style="text-align:center;vertical-align:middle;" colspan="1"> 0.007 </td><td rowspan="6" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cholecystectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (37.5) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Colectomy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Herniorrhaphy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Cesarean section</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Others</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (9.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (25.0) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Pathologic diagnosis</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine tumor</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (25.0) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">&#x02005;&#x0003c;&#x02005;0.001 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Neuroendocrine carcinoma</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (75.0) </td></tr><tr><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">Tumor grade</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (54.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1"> 0.016 </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">27 (90.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (41.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (37.5) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">AJCC stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (64.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1"> 0.004 </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (18.2) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (18.2) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (37.5) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (37.5) </td></tr><tr><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">T stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (68.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1"> 0.008 </td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (9.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (12.5) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">3</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (22.8) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (50.0) </td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (25.0) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">N stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18 (81.8) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (25.0) </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1"> 0.010 </td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (50.0) </td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">2</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (25.0) </td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">M stage</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">0</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (62.5) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1"> 0.014 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (37.5) </td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Tumor group</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">gNET</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (68.1) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (37.5) </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1"> 0.210 </td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">pNET</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (31.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (62.5) </td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Multicentricity</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.545 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Lymphovascular invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (27.2) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (75.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.034 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Perineural invasion</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (22.8) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (75.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.028 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Synaptophysin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">20 (90.9) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (100.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> - </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Chromogranin</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">20 (90.9) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (87.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.286 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (93.3)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Neural cell adhesion molecule 1 (CD56) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (18.2) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (75.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.455 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (40.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Reoperation history</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.545 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Adjuvant therapy</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (13.6) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (62.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.016 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Recurrence</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (4.5) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (75.0) </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Tumor size (cm)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.9 [0.3; 7.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.50 [1.0; 11.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.006 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Mitosis rate (#)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.0 [0.0; 3.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18.0 [1.0; 33.0]</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1"> 0.001 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (100.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1">Ki-67 (%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">2.0 [0.0; 25.0]</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">52.5 [3.0; 90.0]</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1"> 0.001 </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">30 (100.0)</td></tr></tbody></table><table-wrap-foot><fn><p> N, Number of patients analyzed; n, Number of patients; Median [min; max], Median [minimum; maximum]; gNET, Gastrointestinal neuroendocrine tumor; pNET, Hepatopancreatobiliary neuroendocrine tumor.</p></fn></table-wrap-foot></table-wrap><p> Kaplan-Meier survival curves evaluating OS and DFS based on tumor locations are shown in <xref rid="F2" ref-type="fig">Figure 2</xref>. No significant differences were found in OS and DFS between the two subgroups (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.110 and <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.190, respectively). Power analysis revealed that power was %17.8 for recurrence and %32.2 for mortality.</p><fig position="float" id="F2"><label>Figure 2</label><graphic xlink:href="aim-28-29-g002" position="float"/><statement><p>
Comparison of Overall Survival (<bold>A</bold>) and Disease-Free Survival (<bold>B</bold>) between the Study Subgroups</p></statement></fig></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p> Gastroenteropancreatic neuroendocrine tumors are malignancies that originate from neuroendocrine cells.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> The incidence of GEP-NETs is increasing worldwide, with most cases being NETs, some of which may progress slowly. However, highly proliferative tumors, such as G2/3 NETs and NECs characterized by rapid disease progression, are also reported.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> High-grade NETs are characterized by a high proliferation rate (Ki-67&#x02005;&#x0003e;&#x02005;20%) and include both well-differentiated G3 NETs and poorly differentiated NECs.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> While most cases generally involve NETs that typically progress slowly, rapid-progressing NECs can also be encountered in 10&#x02012;20% of cases.<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p> In a study by Komiyama et al spanning 36 years with 43 patients, it was shown that the ratio of NET/NEC and the distribution of tumor stages at diagnosis differed according to the primary site. Patients who underwent surgical resection with G1 and G2 NETs had better prognoses, whereas those with NECs were associated with more advanced disease and poorer prognoses.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> A total of 20% of the patient group included in our study consisted of NEC cases.</p><p> The clinical course of GEP-NETs can vary depending on primary tumor location.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> As a general rule, intestinal NETs, despite having relatively higher malignant potential, tend to progress slowly when metastatic, while gastric and rectal NETs tend to metastasize less frequently.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> The main treatment strategies for GEP-NETs include tumor resection, control of tumor growth and symptoms, and improving quality of life.<sup><xref rid="R24" ref-type="bibr">24</xref></sup></p><p> In a study examining factors affecting survival in GEP-NETs between 1975 and 2015, it was found that patients with pancreatic NETs had worse OS compared to others. It has been demonstrated that survival is shorter in patients over 60 years of age compared to those under 60 years, and in patients with G3 tumors compared to those with G1/G2 tumors.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> The multivariate analysis in the present study showed that male gender, tumor size greater than 2 cm, locoregional or metastatic disease, higher tumor grade, and higher TNM stage negatively impacted OS. Another result of the study is that tumors located in the appendix and small intestine have a more favorable impact on OS compared to other tumor locations.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> In our study, older age, higher tumor grade, advanced TNM stage, and greater tumor size were observed to negatively affect survival, while no significant difference in OS was found between gender groups. Furthermore, we did not observe a significant difference in OS between the gNET and pNET groups.</p><p> A crucial parameter in the characterization of NETs is the histopathological diagnosis, which enables clinicians to ascertain the precise nature, grade, and metastatic potential of the tumors. For NETs, one of the prognostic factors is the tumor&#x02019;s proliferative grade, which is determined by the percentage of tumor cells positive for Ki-67 immunostaining.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> Regarding the recurrence risk of GEP-NETs after curative surgical resection, a study by Merath et al in 2018 involving data from 1,477 patients reported that a high Ki-67 index, invasion of surrounding organs, lymph node positivity, and a tumor diameter greater than 3 cm increased the risk of recurrence.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> In our study, older age, presence of carcinoma diagnosis, higher tumor grade, advanced stages, large tumor diameter, presence of lymphovascular or perineural invasion, increased mitotic count, higher Ki-67 values, and receiving adjuvant therapy were found to increase recurrence rates.</p><p> For patients with GEP-NETs, the Ki-67 proliferation index is an important biological marker. Although both WHO and ENETS use Ki-67 to determine prognostic groups, a definitive cutoff value has not yet been established.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> In our study, an increase in the Ki-67 value was found to increase both mortality and recurrence.</p><p> In a study conducted by Chi et al, which examined the long-term outcomes of patients with GEP-NET, it was found that the 20-year disease-related survival rate for GEP-NET patients who underwent surgical resection was 77.5%. This rate dropped to around 50% for pancreatic tumors, while it was found to be 92.6% for rectal GEP-NET patients.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Another study from the United States also examined the survival outcomes of GEP-NET patients and found that survival was shortest for patients with pancreatic tumors and longest for those with appendiceal and rectal tumors, with a statistically significant difference between the groups.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> In the current literature, not only is there a lack of extensive data on the outcomes of GEP-NET patients, but our literature review also revealed no similar grouping to our current study. Although a marked difference in OS and DFS was observed between our gNET and pNET groups, this difference did not reach statistical significance which may be due to the relatively small sample size of the present study.</p><p> In a cohort study of 155 patients, Liu et al demonstrated that gastric NEC patients had a higher propensity for distant recurrences and a worse prognosis when compared to gastric adenocarcinoma and even poorly differentiated gastric adenocarcinoma.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> It has been proven that the prognosis of localized NETs is favorably consistent with a longer mean OS (&#x02005;&#x0003e;&#x02005;30 years) compared to metastatic NETs (mean OS: 12 months).<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> In our study, the mean OS for the three cases (10%) found to be metastatic was 29.3&#x02005;&#x000b1;&#x02005;25.7 (range: 13&#x02012;59) months, which was observed to be lower than the average OS of the total study group.</p><p> The main limitations of our study are the single-institution context of the study, representing a relatively small sample size from a specific geographic region and its retrospective design. The power analysis indicated low statistical power for detecting effects in both recurrence (17.8%) and mortality (32.2%). However, considering the rarity of GEP-NETs, we believe that the data from the included patients provide valuable insights.</p><p> In conclusion, our study on patients with rare GEP-NETs revealed that although there was a significant difference in survival outcomes between the two subgroups based on tumor locations (gastrointestinal tract and hepatopancreatobiliary system), this difference did not reach statistical significance. On the other hand, demographic, perioperative, and histopathological parameters of the patients had significant effects on recurrence and survival. We believe that prospective studies with larger patient groups will provide additional valuable data to the literature.</p></sec></body><back><ack><p> The authors wish to express their gratitude to Ahmet Naci Emecen, MD, for his valuable contributions to the statistical analysis of this study.</p></ack><fn-group><fn id="n1" fn-type="COI-statement"><p>
<bold>Competing Interests</bold>
</p><p> The corresponding author and all co-authors declare that there are no conflicts of interest. The authors also affirm that this manuscript is not under simultaneous consideration by any other journal or electronic publication and has not been published elsewhere. All authors have adhered to and read the requirements outlined in the Instructions to Authors.</p></fn><fn id="n2" fn-type="other"><p>
<bold>Data Availability Statement</bold>
</p><p> The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></fn><fn id="n3" fn-type="other"><p>
<bold>Ethical Approval</bold>
</p><p> All procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, and ethics committee approval was obtained from the institutional review board (IRB) for the present study [IRB number: 2023/0753]. Informed consent was obtained from all individual participants included in the study. Each author hereby acknowledges that the final state of this manuscript is prepared and sent with his/her approval having been taken.</p></fn><fn id="n4" fn-type="financial-disclosure"><p>
<bold>Funding</bold>
</p><p> The corresponding author and all co-authors declare that no source of funding exists, and that they have no direct or indirect commercial financial incentive associated with publishing this article.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dillon</surname><given-names>JS</given-names></name>
</person-group><article-title>Workup of gastroenteropancreatic neuroendocrine tumors</article-title><source>Surg Oncol Clin N Am</source><year>2020</year><volume>29</volume><issue>2</issue><fpage>165</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.soc.2019.10.002</pub-id><pub-id pub-id-type="pmid">32151354</pub-id>
</element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dasari</surname><given-names>A</given-names></name>
<name><surname>Shen</surname><given-names>C</given-names></name>
<name><surname>Halperin</surname><given-names>D</given-names></name>
<name><surname>Zhao</surname><given-names>B</given-names></name>
<name><surname>Zhou</surname><given-names>S</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<etal/>
</person-group><article-title>Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States</article-title><source>JAMA Oncol</source><year>2017</year><volume>3</volume><issue>10</issue><fpage>1335</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.0589</pub-id><pub-id pub-id-type="pmid">28448665</pub-id>
</element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frilling</surname><given-names>A</given-names></name>
<name><surname>Akerstr&#x000f6;m</surname><given-names>G</given-names></name>
<name><surname>Falconi</surname><given-names>M</given-names></name>
<name><surname>Pavel</surname><given-names>M</given-names></name>
<name><surname>Ramos</surname><given-names>J</given-names></name>
<name><surname>Kidd</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Neuroendocrine tumor disease: an evolving landscape</article-title><source>Endocr Relat Cancer</source><year>2012</year><volume>19</volume><issue>5</issue><fpage>R163</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1530/erc-12-0024</pub-id><pub-id pub-id-type="pmid">22645227</pub-id>
</element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Njere</surname><given-names>I</given-names></name>
<name><surname>Smith</surname><given-names>LL</given-names></name>
<name><surname>Thurairasa</surname><given-names>D</given-names></name>
<name><surname>Malik</surname><given-names>R</given-names></name>
<name><surname>Jeffrey</surname><given-names>I</given-names></name>
<name><surname>Okoye</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>Systematic review and meta-analysis of appendiceal carcinoid tumors in children</article-title><source>Pediatr Blood Cancer</source><year>2018</year><volume>65</volume><issue>8</issue><fpage>e27069</fpage><pub-id pub-id-type="doi">10.1002/pbc.27069</pub-id><pub-id pub-id-type="pmid">29745005</pub-id>
</element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallotti</surname><given-names>A</given-names></name>
<name><surname>Johnston</surname><given-names>RP</given-names></name>
<name><surname>Bonaffini</surname><given-names>PA</given-names></name>
<name><surname>Ingkakul</surname><given-names>T</given-names></name>
<name><surname>Deshpande</surname><given-names>V</given-names></name>
<name><surname>Fern&#x000e1;ndez-del Castillo</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy</article-title><source>AJR Am J Roentgenol</source><year>2013</year><volume>200</volume><issue>2</issue><fpage>355</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.2214/ajr.11.8037</pub-id><pub-id pub-id-type="pmid">23345357</pub-id>
</element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halfdanarson</surname><given-names>TR</given-names></name>
<name><surname>Rabe</surname><given-names>KG</given-names></name>
<name><surname>Rubin</surname><given-names>J</given-names></name>
<name><surname>Petersen</surname><given-names>GM</given-names></name>
</person-group><article-title>Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><issue>10</issue><fpage>1727</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn351</pub-id><pub-id pub-id-type="pmid">18515795</pub-id>
</element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vortmeyer</surname><given-names>AO</given-names></name>
<name><surname>Huang</surname><given-names>S</given-names></name>
<name><surname>Lubensky</surname><given-names>I</given-names></name>
<name><surname>Zhuang</surname><given-names>Z</given-names></name>
</person-group><article-title>Non-islet origin of pancreatic islet cell tumors</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><issue>4</issue><fpage>1934</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031575</pub-id><pub-id pub-id-type="pmid">15070966</pub-id>
</element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klimstra</surname><given-names>DS</given-names></name>
<name><surname>Modlin</surname><given-names>IR</given-names></name>
<name><surname>Coppola</surname><given-names>D</given-names></name>
<name><surname>Lloyd</surname><given-names>RV</given-names></name>
<name><surname>Suster</surname><given-names>S</given-names></name>
</person-group><article-title>The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems</article-title><source>Pancreas</source><year>2010</year><volume>39</volume><issue>6</issue><fpage>707</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1097/MPA.0b013e3181ec124e</pub-id><pub-id pub-id-type="pmid">20664470</pub-id>
</element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>K</given-names></name>
<name><surname>Detlefsen</surname><given-names>S</given-names></name>
<name><surname>Brusgaard</surname><given-names>K</given-names></name>
<name><surname>Christesen</surname><given-names>HT</given-names></name>
</person-group><article-title>Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data</article-title><source>Front Endocrinol (Lausanne)</source><year>2024</year><volume>15</volume><fpage>1351624</fpage><pub-id pub-id-type="doi">10.3389/fendo.2024.1351624</pub-id><pub-id pub-id-type="pmid">38868744</pub-id>
</element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cives</surname><given-names>M</given-names></name>
<name><surname>Strosberg</surname><given-names>JR</given-names></name>
</person-group><article-title>Gastroenteropancreatic Neuroendocrine Tumors</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><issue>6</issue><fpage>471</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3322/caac.21493</pub-id><pub-id pub-id-type="pmid">30295930</pub-id>
</element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Man</surname><given-names>D</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Shen</surname><given-names>Z</given-names></name>
<name><surname>Zhu</surname><given-names>X</given-names></name>
</person-group><article-title>Prognosis of patients with neuroendocrine tumor: a SEER database analysis</article-title><source>Cancer Manag Res</source><year>2018</year><volume>10</volume><fpage>5629</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.2147/cmar.S174907</pub-id><pub-id pub-id-type="pmid">30519109</pub-id>
</element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cherif</surname><given-names>R</given-names></name>
<name><surname>Gaujoux</surname><given-names>S</given-names></name>
<name><surname>Couvelard</surname><given-names>A</given-names></name>
<name><surname>Dokmak</surname><given-names>S</given-names></name>
<name><surname>Vuillerme</surname><given-names>MP</given-names></name>
<name><surname>Ruszniewski</surname><given-names>P</given-names></name>
<etal/>
</person-group><article-title>Parenchyma-sparing resections for pancreatic neuroendocrine tumors</article-title><source>J Gastrointest Surg</source><year>2012</year><volume>16</volume><issue>11</issue><fpage>2045</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1007/s11605-012-2002-7</pub-id><pub-id pub-id-type="pmid">22911124</pub-id>
</element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Partelli</surname><given-names>S</given-names></name>
<name><surname>Bartsch</surname><given-names>DK</given-names></name>
<name><surname>Capdevila</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Knigge</surname><given-names>U</given-names></name>
<name><surname>Niederle</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours</article-title><source>Neuroendocrinology</source><year>2017</year><volume>105</volume><issue>3</issue><fpage>255</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1159/000464292</pub-id><pub-id pub-id-type="pmid">28237989</pub-id>
</element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daskalakis</surname><given-names>K</given-names></name>
<name><surname>Karakatsanis</surname><given-names>A</given-names></name>
<name><surname>Hessman</surname><given-names>O</given-names></name>
<name><surname>Stuart</surname><given-names>HC</given-names></name>
<name><surname>Welin</surname><given-names>S</given-names></name>
<name><surname>Tiensuu Janson</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival</article-title><source>JAMA Oncol</source><year>2018</year><volume>4</volume><issue>2</issue><fpage>183</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.3326</pub-id><pub-id pub-id-type="pmid">29049611</pub-id>
</element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grozinsky-Glasberg</surname><given-names>S</given-names></name>
<name><surname>Alexandraki</surname><given-names>KI</given-names></name>
<name><surname>Barak</surname><given-names>D</given-names></name>
<name><surname>Doviner</surname><given-names>V</given-names></name>
<name><surname>Reissman</surname><given-names>P</given-names></name>
<name><surname>Kaltsas</surname><given-names>GA</given-names></name>
<etal/>
</person-group><article-title>Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? Clinical experience and review of the literature</article-title><source>Neuroendocrinology</source><year>2013</year><volume>98</volume><issue>1</issue><fpage>31</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000343801</pub-id><pub-id pub-id-type="pmid">23051855</pub-id>
</element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramage</surname><given-names>JK</given-names></name>
<name><surname>De Herder</surname><given-names>WW</given-names></name>
<name><surname>Delle Fave</surname><given-names>G</given-names></name>
<name><surname>Ferolla</surname><given-names>P</given-names></name>
<name><surname>Ferone</surname><given-names>D</given-names></name>
<name><surname>Ito</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>ENETS consensus guidelines update for colorectal neuroendocrine neoplasms</article-title><source>Neuroendocrinology</source><year>2016</year><volume>103</volume><issue>2</issue><fpage>139</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1159/000443166</pub-id><pub-id pub-id-type="pmid">26730835</pub-id>
</element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anthony</surname><given-names>LB</given-names></name>
<name><surname>Strosberg</surname><given-names>JR</given-names></name>
<name><surname>Klimstra</surname><given-names>DS</given-names></name>
<name><surname>Maples</surname><given-names>WJ</given-names></name>
<name><surname>O&#x02019;Dorisio</surname><given-names>TM</given-names></name>
<name><surname>Warner</surname><given-names>RR</given-names></name>
<etal/>
</person-group><article-title>The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum</article-title><source>Pancreas</source><year>2010</year><volume>39</volume><issue>6</issue><fpage>767</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1097/MPA.0b013e3181ec1261</pub-id><pub-id pub-id-type="pmid">20664474</pub-id>
</element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caplin</surname><given-names>ME</given-names></name>
<name><surname>Pavel</surname><given-names>M</given-names></name>
<name><surname>&#x00106;wik&#x00142;a</surname><given-names>JB</given-names></name>
<name><surname>Phan</surname><given-names>AT</given-names></name>
<name><surname>Raderer</surname><given-names>M</given-names></name>
<name><surname>Sedl&#x000e1;&#x0010d;kov&#x000e1;</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>Lanreotide in metastatic enteropancreatic neuroendocrine tumors</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>3</issue><fpage>224</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1316158</pub-id><pub-id pub-id-type="pmid">25014687</pub-id>
</element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chi</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>1396</fpage><pub-id pub-id-type="doi">10.1186/s12889-024-18845-8</pub-id><pub-id pub-id-type="pmid">38789981</pub-id>
</element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borghesani</surname><given-names>M</given-names></name>
<name><surname>Reni</surname><given-names>A</given-names></name>
<name><surname>Lauricella</surname><given-names>E</given-names></name>
<name><surname>Rossi</surname><given-names>A</given-names></name>
<name><surname>Moscarda</surname><given-names>V</given-names></name>
<name><surname>Trevisani</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>Efficacy and toxicity analysis of mFOLFIRINOX in high-grade gastroenteropancreatic neuroendocrine neoplasms</article-title><source>J Natl Compr Canc Netw</source><year>2024</year><volume>22</volume><issue>5</issue><fpage>e247005</fpage><pub-id pub-id-type="doi">10.6004/jnccn.2024.7005</pub-id><pub-id pub-id-type="pmid">38744314</pub-id>
</element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Komiyama</surname><given-names>S</given-names></name>
<name><surname>Okusaka</surname><given-names>T</given-names></name>
<name><surname>Maruki</surname><given-names>Y</given-names></name>
<name><surname>Ohba</surname><given-names>A</given-names></name>
<name><surname>Nagashio</surname><given-names>Y</given-names></name>
<name><surname>Kondo</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Clinicopathological findings and treatment outcomes of patients with primary hepatobiliary neuroendocrine neoplasms: a retrospective single-institution analysis</article-title><source>Intern Med</source><year>2024</year><volume>63</volume><issue>7</issue><fpage>891</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.2016-23</pub-id><pub-id pub-id-type="pmid">37612088</pub-id>
</element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartrampf</surname><given-names>PE</given-names></name>
<name><surname>Serfling</surname><given-names>SE</given-names></name>
<name><surname>Higuchi</surname><given-names>T</given-names></name>
<name><surname>Bojunga</surname><given-names>J</given-names></name>
<name><surname>Weich</surname><given-names>A</given-names></name>
<name><surname>Werner</surname><given-names>RA</given-names></name>
</person-group><article-title>[Clinical significance of neuroendocrine tumors: incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management]</article-title><source>Radiologie (Heidelb)</source><year>2024</year><volume>64</volume><issue>7</issue><fpage>536</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s00117-024-01315-y.[German]</pub-id><pub-id pub-id-type="pmid">38777918</pub-id>
</element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>S</given-names></name>
<name><surname>Dasari</surname><given-names>A</given-names></name>
</person-group><article-title>Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?</article-title><source>Curr Oncol Rep</source><year>2021</year><volume>23</volume><issue>4</issue><fpage>43</fpage><pub-id pub-id-type="doi">10.1007/s11912-021-01029-7</pub-id><pub-id pub-id-type="pmid">33719003</pub-id>
</element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pavel</surname><given-names>M</given-names></name>
<name><surname>Lahner</surname><given-names>H</given-names></name>
<name><surname>H&#x000f6;rsch</surname><given-names>D</given-names></name>
<name><surname>Rinke</surname><given-names>A</given-names></name>
<name><surname>Denecke</surname><given-names>T</given-names></name>
<name><surname>Koch</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Combined lanreotide autogel and temozolomide treatment of progressive pancreatic and intestinal neuroendocrine tumors: the phase II SONNET study</article-title><source>Oncologist</source><year>2024</year><volume>29</volume><issue>5</issue><fpage>e643</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyad325</pub-id><pub-id pub-id-type="pmid">38206830</pub-id>
</element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Z</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Dai</surname><given-names>S</given-names></name>
<name><surname>Chen</surname><given-names>M</given-names></name>
<name><surname>Li</surname><given-names>F</given-names></name>
<name><surname>Sun</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States</article-title><source>JAMA Netw Open</source><year>2021</year><volume>4</volume><issue>9</issue><fpage>e2124750</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.24750</pub-id><pub-id pub-id-type="pmid">34554237</pub-id>
</element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zehra</surname><given-names>T</given-names></name>
<name><surname>Shams</surname><given-names>M</given-names></name>
<name><surname>Ali</surname><given-names>R</given-names></name>
<name><surname>Jafri</surname><given-names>A</given-names></name>
<name><surname>Khurshid</surname><given-names>A</given-names></name>
<name><surname>Erum</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Use of novel open-source deep learning platform for quantification of Ki-67 in neuroendocrine tumors - analytical validation</article-title><source>Int J Gen Med</source><year>2023</year><volume>16</volume><fpage>5665</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.2147/ijgm.S443952</pub-id><pub-id pub-id-type="pmid">38077478</pub-id>
</element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merath</surname><given-names>K</given-names></name>
<name><surname>Bagante</surname><given-names>F</given-names></name>
<name><surname>Beal</surname><given-names>EW</given-names></name>
<name><surname>Lopez-Aguiar</surname><given-names>AG</given-names></name>
<name><surname>Poultsides</surname><given-names>G</given-names></name>
<name><surname>Makris</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: an analysis of the US Neuroendocrine Tumor Study Group</article-title><source>J Surg Oncol</source><year>2018</year><volume>117</volume><issue>5</issue><fpage>868</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/jso.24985</pub-id><pub-id pub-id-type="pmid">29448303</pub-id>
</element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JY</given-names></name>
<name><surname>Hong</surname><given-names>SM</given-names></name>
<name><surname>Ro</surname><given-names>JY</given-names></name>
</person-group><article-title>Recent updates on grading and classification of neuroendocrine tumors</article-title><source>Ann Diagn Pathol</source><year>2017</year><volume>29</volume><fpage>11</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.anndiagpath.2017.04.005</pub-id><pub-id pub-id-type="pmid">28807335</pub-id>
</element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chi</surname><given-names>W</given-names></name>
<name><surname>Warner</surname><given-names>RRP</given-names></name>
<name><surname>Chan</surname><given-names>DL</given-names></name>
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Segelov</surname><given-names>E</given-names></name>
<name><surname>Strosberg</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Long-term outcomes of gastroenteropancreatic neuroendocrine tumors</article-title><source>Pancreas</source><year>2018</year><volume>47</volume><issue>3</issue><fpage>321</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/mpa.0000000000001005</pub-id><pub-id pub-id-type="pmid">29401168</pub-id>
</element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Lin</surname><given-names>Q</given-names></name>
<name><surname>Cui</surname><given-names>R</given-names></name>
<name><surname>Tang</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data</article-title><source>BMC Gastroenterol</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>408</fpage><pub-id pub-id-type="doi">10.1186/s12876-023-03041-6</pub-id><pub-id pub-id-type="pmid">37993767</pub-id>
</element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamarca</surname><given-names>A</given-names></name>
<name><surname>Clouston</surname><given-names>H</given-names></name>
<name><surname>Barriuso</surname><given-names>J</given-names></name>
<name><surname>McNamara</surname><given-names>MG</given-names></name>
<name><surname>Frizziero</surname><given-names>M</given-names></name>
<name><surname>Mansoor</surname><given-names>W</given-names></name>
<etal/>
</person-group><article-title>Follow-up recommendations after curative resection of well-differentiated neuroendocrine tumours: review of current evidence and clinical practice</article-title><source>J Clin Med</source><year>2019</year><volume>8</volume><issue>10</issue><fpage>1630</fpage><pub-id pub-id-type="doi">10.3390/jcm8101630</pub-id><pub-id pub-id-type="pmid">31590343</pub-id>
</element-citation></ref></ref-list></back></article>